Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 28, 2014, 41 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,490.00 to $31,239,250.00.

Highlighted Stocks Traded by Insiders:

bluebird bio (BLUE) - FREE Research Report

Leschly Nick, who is President and CEO at bluebird bio, sold 33,900 shares at $40.22 on Oct. 28, 2014. Following this transaction, the President and CEO owned 273,170 shares meaning that the stake was reduced by 11.04% with the 33,900-share transaction.

The shares most recently traded at $40.68, up $0.46, or 1.13% since the insider transaction. Historical insider transactions for bluebird bio go as follows:

  • 4-Week # shares bought: 2,941
  • 4-Week # shares sold: 8,000
  • 12-Week # shares bought: 2,941
  • 12-Week # shares sold: 143,300
  • 24-Week # shares bought: 2,941
  • 24-Week # shares sold: 238,583

The average volume for bluebird bio has been 345,700 shares per day over the past 30 days. Bluebird bio has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 95.52% year-to-date as of the close of trading on Tuesday.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company has a P/E ratio of 6.2. Currently, there are 5 analysts who rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BLUE - FREE

TheStreet Quant Ratings rates bluebird bio as a sell. The area that we feel has been the company's primary weakness has been its feeble growth in its earnings per share. Get the full bluebird bio Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CH Robinson Worldwide (CHRW) - FREE Research Report

Campbell Ben G, who is VP-General Counsel & Secretary at CH Robinson Worldwide, sold 2,240 shares at $72.00 on Oct. 28, 2014. Following this transaction, the VP-General Counsel & Secretary owned 33,274 shares meaning that the stake was reduced by 6.31% with the 2,240-share transaction.

The shares most recently traded at $72.50, up $0.50, or 0.69% since the insider transaction. Historical insider transactions for CH Robinson Worldwide go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 2,100
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 7,750
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 45,644

The average volume for CH Robinson Worldwide has been 1.4 million shares per day over the past 30 days. CH Robinson Worldwide has a market cap of $10.6 billion and is part of the services sector and transportation industry. Shares are up 23.98% year-to-date as of the close of trading on Tuesday.

C.H. Robinson Worldwide, Inc., a third party logistics company, provides freight transportation services and logistics solutions to companies in various industries worldwide. The stock currently has a dividend yield of 1.95%. The company has a P/E ratio of 26.2. Currently, there are 2 analysts who rate CH Robinson Worldwide a buy, 2 analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHRW - FREE

TheStreet Quant Ratings rates CH Robinson Worldwide as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CH Robinson Worldwide Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Bristol-Myers Squibb Company (BMY) - FREE Research Report

Andreotti Lamberto, who is Chief Executive Officer at Bristol-Myers Squibb Company, sold 50,000 shares at $53.00 on Oct. 28, 2014. Following this transaction, the Chief Executive Officer owned 510,809 shares meaning that the stake was reduced by 8.92% with the 50,000-share transaction.

The shares most recently traded at $54.00, up $1.00, or 1.85% since the insider transaction. Historical insider transactions for Bristol-Myers Squibb Company go as follows:

  • 4-Week # shares sold: 150,000
  • 12-Week # shares sold: 254,106
  • 24-Week # shares sold: 327,829

The average volume for Bristol-Myers Squibb Company has been 5.6 million shares per day over the past 30 days. Bristol-Myers Squibb Company has a market cap of $88.8 billion and is part of the health care sector and drugs industry. Shares are up 1.98% year-to-date as of the close of trading on Tuesday.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock currently has a dividend yield of 2.69%. The company has a P/E ratio of 33.0. Currently, there are 10 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMY - FREE

TheStreet Quant Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null